Gene therapy of human cancer using genetically engineered autologous lymphocytes is dependent on the identification of highly reactive T cell receptors (TCR) with anti-tumor activity. We immunized HLA transgenic mice and also conducted high-throughput screening of human lymphocytes to generate TCR highly reactive to melanoma/melanocyte antigens. Genes encoding these TCR were engineered into retroviral vectors and used to transduce autologous peripheral lymphocytes administered to 36 patients with metastatic melanoma. Transduced patient lymphocytes were
Introduction
Tumor associated antigens have been identified on a wide variety of human cancers.
Many of these antigens are normal, non-mutated self proteins selectively expressed or overexpressed on cancers 1 . Antigens such as MART-1 and gp100 are expressed on melanomas and normal melanocytes in the skin, eye and ear 2, 3 . Other cancer-associated antigens such as carcinoembryonic antigen (CEA), Her2/neu and Muc-1 are expressed at low levels on some normal tissues whereas antigens such as NY-ESO-1 and the MAGE family of proteins are expressed on fetal tissue and the adult testes but not on other normal adult tissues 4 . The presence of these normal proteins during fetal development leads to central tolerance based on negative selection in the thymus of lymphocyte clones bearing high-affinity self-reactive T cell receptors (TCR). Occasionally, lymphocytes bearing high-affinity TCR escape thymic deletion, and in these instances mechanisms of peripheral tolerance can suppress their activity 5 .
Cell transfer therapies have emerged as a tool to overcome the limitations imposed by both central and peripheral tolerance [6] [7] [8] [9] . Transfer of anti-tumor T cells to lymphodepleted mice can mediate the rejection of large, vascularized tumors 10 and the administration of naturally occurring anti-melanoma tumor infiltrating lymphocytes (TIL) can mediate objective cancer regressions in 51-72 % of lymphodepleted patients with metastatic melanoma 7, 8, 11 .
A major obstacle to the widespread application of cell transfer therapies is the difficulty in identifying human T cells with anti-tumor recognition. Only about half of melanomas
For personal use only. on April 1, 2017 . by guest www.bloodjournal.org From reproducibly give rise to anti-tumor TIL 12 , and other cancer types only rarely contain identifiable tumor-reactive lymphocytes. An alternative to finding these natural tumor reactive cells for every patient is the transfer to normal lymphocytes of tumor reactive TCR genes recognizing shared tumor antigens.
In a prior study we identified a TCR (MSGV1AIB, here referred to as DMF4) that recognized the MART-1 melanoma-melanocyte antigen cloned from the TIL of a resected melanoma lesion 13 . We treated 31 patients with autologous PBL transduced with genes encoding this receptor (17 were previously reported) 14 and four patients (13 % ) experienced an objective regression of metastatic melanoma. None of the 31 patients exhibited skin rash or normal melanocyte toxicity in the eye or ear. The DMF4 receptor had only moderate ability to recognize limiting amounts of antigen and we hypothesized that a more highly reactive TCR might be clinically more effective in recognizing malignant cells that expressed the target antigen.
We thus generated a high avidity TCR from a human T cell that recognized the MART-1:27-35 epitope (here referred to as DMF5) 15 . The gp100:154-162 epitope from the gp100 melanoma-melanocyte antigen is the most highly expressed peptide from this protein, displayed on the cell surface. Attempts to generate a high avidity human TCR against this epitope were unsuccessful. We were able however, to generate a highly avid TCR against this epitope in HLA-A2 transgenic mice. These anti-MART-1 and antigp100 TCRs were used to treat patients with metastatic melanoma.
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Materials and Methods

Patients
Thirty-six patients with metastatic melanoma were treated at the Surgery Branch, NCI, Bethesda MD, between July 2007 and March 2008, in protocols approved by the IRB and FDA, 20 with TCR recognizing the HLA-A*02-restricted melanoma antigen MART-1 (DMF5) 15 , and 16 with TCR recognizing the HLA-A*02-restricted melanoma antigen gp100(154) 16 . All patients gave informed consent for treatment in accordance with the Declaration of Helsinki. Patients were HLA-A*02P + P , 18 years of age or older, had measurable metastatic melanoma; ECOG status 0 or 1. All patients had progressed after prior treatment with IL-2/Aldesleukin and had tumors that expressed the appropriate antigen (MART-1/Melan-A or gp100/HMB45). Contraindications were: concurrent major medical illnesses; any form of primary or secondary immunodeficiency; severe hypersensitivity to any of the agents used in this study; contraindications for high-dose IL-2 administration; systemic steroid treatment within 30 days prior to treatment; untreated intracranial metastases >1.0 cm in diameter.
TCR recognizing shared melanoma antigens
The generation of the DMF5 TCR has been previously described 15 . The patient from whom the MART-1 reactive TCR was derived experienced vitiligo but no eye or ear toxicity. To generate a high avidity TCR against the gp100:154-162 epitope, HLA-A*0201 (A2.1) mice were immunized twice with the human gp100:154-162 peptide and the I-A b -binding synthetic T helper peptide representing residues 128-140 of the hepatitis B virus core protein (HBV-Core) emulsified in incomplete Freund's adjuvant. Seven days
For personal use only. on April 1, 2017. by guest www.bloodjournal.org From after the second immunization, splenocytes were stimulated in vitro with equal numbers of irradiated, LPS activated, A2.1 transgenic mouse splenocytes pulsed with 0.01 μg/ml of human gp100:154-162 peptide and 10 μg/ml of human β2-microglobulin in media containing 5 IU IL-2. Eight days after a third stimulation, T cells were cloned by limiting dilution in presence of irradiated T2 cells pulsed with 0.01 μg/ml of human gp100:154-162 peptide and irradiated C57Bl/6 splenocytes. 5' RACE TCR isolation and RNA electroporation into donor PBL was as previously described 15 . The gp100(154) TCR conferring the highest anti-tumor avidity to donor PBL functioned independently of CD4 or CD8 co-receptor, and was selected for clinical use.
Retroviral gene therapy vectors
pMSGV1 is derived from pMSGV murine stem cell virus (MSCV) long terminal repeat containing an extended gag region and Kozak sequence 13 . Vector pMSGV1 gp100(154)-AIB was produced by linking the TCRα via an IRES element followed by insertion of the TCRβ chain. Vector pMSGV DMF5 f2A was generated by introducing DMF5 TCRα cDNA 15 followed by a furin T2A cleavage sequence and DMF5 TCRβ. Clinical grade cGMP-quality retroviral supernatants were produced by the National Gene Vector
Laboratories at Indiana University. Patient PBL were stimulated with anti-CD3 mAb OKT-3 2 days prior to transduction using Retronectin (Takara Corp, Japan) coated plates, per manufacturer's recommendations. clone were isolated and equivalent amounts of RNA were generated in vitro and transferred into both Jurkat and donor PBL. After transferring the same amount of exogenous TCR (evaluated by CD3 surface expression in Jurkat cells), 15 the higher avidity DMF5 and gp100(154) TCR conferred higher reactivity to donor PBL than the previously identified DMF4 in recognizing tumor antigen. (Fig. 1A) . The genes encoding the alpha and beta chains from these two receptors, gp100(154) and DMF5, were each cloned into bicistronic gamma-retroviral vectors utilizing an internal ribosome entry site (IRES) or a furin 2-A picornavirus-like cleavage sequence (f2A) respectively, to drive expression of the second gene (Fig. 1B) . These retroviral vectors were used to transduce normal human peripheral lymphocytes (Fig. 2) . It has been demonstrated that DMF4
binds tetramer weakly, under-representing the amount of surface TCR 14, 15 , a result also observed here ( Fig 
Administration of TCR transduced autologous PBL to patients with metastatic melanoma
To investigate the in vivo activity of autologous cells transduced with these highly reactive TCR, 36 patients with heavily pretreated, progressive metastatic melanoma received transduced cells (20 patients with DMF5 and 16 with gp100(154)), following a lymphodepleting preparative regimen to deplete endogenous circulating lymphocytes 8 .
Patient demographics and treatment details are presented in Tables 1 and 2 . Intravenous IL-2 was administered to patients starting 8 hours after adoptive cell transfer, and continued every 8 hours for up to three days. All of the patients were refractory to prior Based on tetramer staining, the mean transduction efficiencies for cells administered to these 36 patients were 71 % and 82 % for DMF5 and gp100(154) TCR respectively ( Tables   1,2 ). All treatment cells showed high levels of specific reactivity against cognate antigenbearing tumor targets as assessed by intracellular cytokine staining and ELISPOT analysis (both interferon-gamma (IFNγ) and IL-2) ( Tables 1,2 ) and for IFNγ release (Table 3) and target cell lysis (data not shown).
Adoptively transferred highly reactive anti-tumor cells persisted at high levels in patients
In prior trials of patients receiving unmodified TIL, in vivo cell persistence of the transferred cells highly correlated with anti-tumor response 18 . We thus evaluated the persistence of the human DMF5 and the murine gp100(154) TCR transduced cells using tetramer binding and ELISPOT assays. All patients had measurable levels (≥ 1%) of tetramer-positive T cells in their circulation at 1 month post-treatment (Fig. 3A,B) . There was no difference in the persistence of cells bearing the human DMF5 TCR (22 + /-6 % ) or the murine gp100(154) TCR (22 + /-5 % ; P = 0.4) (Fig. 3B) . To measure functional recognition of tumor cells, post-treatment PBL were co-cultured with MHC matched or mismatched melanomas and cell reactivity was assessed using ELISPOT and intracellular FACS assays (Fig. 3) . Interferon-gamma ELISPOT assay showed persistence (>20 specific spots/100,000 cells) of tumor-reactive transduced cells in 11/20 DMF5 and 7/16
For personal use only. on April 1, 2017. by guest www.bloodjournal.org From gp100(154) patients (Fig. 3B) . Similarly, 11 and 7 of the DMF5 and gp100(154) patients, respectively exhibited persistence of active cells via IL-2 ELISPOT assays of PBL at one month post treatment (Fig. 3A) . At this same one month time point specific intracellular IFNγ staining was seen in 12 of the 20 DMF5 patients (Fig. 3B) . Thus, as determined in multiple assays, both murine-and human-derived TCR gene-modified cells persisted in the circulation at one month in the majority of patients. Comparing between responding and non-responding patients, responding patients all had highly persistent tumor-reactive cells at ≥ 10 % tetramer positive T cells in the blood, one month after treatment. However, some non-responding patients also had high levels of active persistent cells, suggesting that persistence may be necessary, but not sufficient to cause tumor regression in patients. 
Clinical course of patients receiving TCR transduced cells: reactivity against normal tissues
The clinical course of patients receiving the highly tumor-reactive DMF5 and gp100(154) TCR transduced cells was quite different from that of our prior study with the DMF4 receptor 14 . In the current trial, increased levels of IFNγ were detected in the serum of patients, peaking around day 3-5 post treatment (Fig. 5A) . The mean peak IFNγ serum values for patients receiving the improved DMF5 and gp100(154) gene constructs were 128 pg/mL and 210 pg/mL, respectively, compared with 14 pg/mL for the previous DMF4 patients (P = 0.03) (Fig. 5B) . As IFNγ is an effector cytokine produced by activated T lymphocytes, and patients remained depleted of their endogenous lymphocytes during the first week following the preparative lymphodepletion, it is presumed that the transferred cells were the source of this cytokine production.
At the time of this cytokine surge, 29 of the 36 patients in the current trial exhibited a widespread erythematous skin rash that on biopsy showed prominent epidermal spongiosis and necrotic epidermal keratinocytes, with a dense infiltrate of CD3 + T lymphocytes (predominantly CD8 + ) (Fig. 6A) . Surprisingly, there was destruction of epidermal melanocytes in all biopsies performed on 14 DMF5 patients and 13 gp100(154) patients, starting as early as day 5 post-treatment (Fig. 6A) , although rare remaining melanocytes were sometimes observed around hair follicles. This loss of melanocytes coincided with the dermal and epidermal infiltration of lymphocytes as well as evidence of vitiligo in patients upon later follow-up. This rash gradually subsided over several days without treatment in all patients. To elucidate the factors inciting the rash and the lymphocyte infiltration into skin, we studied two patients who presented with preexisting patchy vitiligo. These two patients developed a rash only in pigmented and not in vitiliginous skin (Fig. 6B) . Biopsies following treatment revealed diffuse infiltrates of (Tables 1,2; Fig. 6C ). Two patients developed synechiae of the iris that were asymptomatic (Fig. 6C) . In all patients, ocular findings reverted to normal. Sampling of the eye anterior chamber fluid in one patient with uveitis who received the DMF5 transduced cells revealed a predominance of MART-1 tetramer-positive CD3 + T-cells by FACS analysis (Fig. 6D) , indicating trafficking of gene-modified cells into the eye.
Melanocytic cells also exist in the striae vascularis of the inner ear. Though none of the patients in the prior DMF4 trial exhibited hearing loss, audiometric exams revealed evidence of hearing loss in 10/20 of the DMF5 patients starting about one week after treatment (Table 1 and Fig. 6E ), 7 of whom received intratympanic steroid injections. All patients improved, and the grade 3 hearing losses resolved or improved to a grade 1 or 2 with the exception of two patients who died of progressive metastatic melanoma before they were retested. Five of the sixteen gp100(154) patients developed mild hearing loss (Table 2) , only one of whom required treatment and continues to have mild residual changes. Nine of the 36 patients experienced inner-ear related dizziness that responded to treatment. This constellation of symptoms is similar to that observed in patients with Vogt-Koyanagi-Harada disease 20 , thought to result from autoimmune destruction of melanocytes located in the eye, the inner ear, skin, and hair. There were no off-target autoimmune effects observed in any patients.
DMF4 and DMF5 TCR recognize the same MART-1:27-35 epitope and were derived from the same melanoma patient 15 . The improved ability of transduced cells expressing the DMF5 or gp100(154) TCR to recognize target antigens in the skin, eye and ear and to
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Anti-tumor impact of the TCR transduced cells
One patient who received DMF5 transduced cells underwent a series of sequential biopsies of subcutaneous metastatic lesions before and after treatment. Beginning at about five days after treatment the biopsies revealed an increasing infiltration of CD8 + T lymphocytes throughout the tumor that coincided with the progressive necrosis and partial regression of his tumors (Fig. 7A,B) . Growth of lymphocytes from resected lesions at days 9, 15 and 26 revealed > 97 % MART-1 tetramer positive lymphocytes ( (Tables 1,2 ). Tumors regressed in multiple organs including the brain, lung, liver, lymph nodes and subcutaneous sites (Fig. 7D-F ). There were no treatment related deaths and all patients recovered from treatment.
In analyzing the 36 patients there was no correlation between the number of cells administered and the likelihood of a clinical response, with some responding patients receiving a log fewer cells than others (Table 1 ). There was also no correlation between
For personal use only. on April 1, 2017. by guest www.bloodjournal.org From -18 -clinical response and the duration the cells were grown ex-vivo, or whether they received one or two OKT-3 stimulations. There was a correlation with clinical response and the persistence of administered cells at one month as assessed by ELISPOT analysis of both specific IFNγ and IL-2 release (both P = 0.02) (Fig. 3B) . Although all responding patients had ≥ 10 % tetramer positive cells persisting in blood at one month, this parameter did not correlate with response (P = 0.4) (Fig. 3B ). The recognition of normal quiescent cells expressing the targeted cancer antigen raises obvious questions concerning the toxicity of this gene therapy approach. These results paralleled our findings in a murine melanoma model which showed an association of ocular toxicity and anti-tumor activity using gp100 as the target antigen 22 , although clinically the local application of steroids attenuated normal tissue toxicity for patients treated with these melanocyte specific TCR. These findings emphasize the importance of the targeted tumor antigen. It may be highly effective to target differentiation antigens on cancers that arise in non-essential organs such as the prostate, ovary, breast, and thyroid.
Other cancers have higher expression of differentiation antigens such as CEA and Muc-1 than are expressed in normal tissues and this may create a therapeutic window to be exploited. The cancer-testes class of antigens not expressed on normal adult tissues may be ideal targets for this approach. In any case, the risks versus benefits of infusing highly reactive self-antigen specific TCRs must be carefully considered. % objective cancer response rates seen with the DMF5 and gp100(154) TCR were lower than the 51-72 % response rates seen with the use of autologous TIL screened and grown individually from each patient's resected tumor 7, 8, 11 . Anterior uveitis and ototoxicity were seen in six of 93 (6.5 % ) and only one of 93 (1.1 % ) melanoma patients treated with TIL, respectively, in contrast with the 41.7 % incidence of both toxicities seen in the current trial (P < 0.0001), sometimes in the absence of tumor regression, implying that the shared melanoma/melanocyte antigens may not be the predominant targets of therapeutic TIL. Although many TIL do recognize the MART-1 and gp100 antigens, T cell clones have been isolated from many clinically effective TIL that recognize mutated or unidentified antigens as well and these may also be responsible for the anti-tumor effects of TIL transfer. Alternatively, differences in homing molecules or other phenotypic differences between blood and tumor-derived lymphocytes may account for this finding.
Several patients exhibited melanocyte toxicity without experiencing tumor rejection.
Treating patients with low (DMF4) and high (DMF5) avidity TCR recognizing the same MART-1 antigen resulted in 13 % (4/34) and 30 % (6/20) objective tumor responses, respectively, suggesting that increased TCR avidity may improve tumor rejection.
However, due to the small sample numbers, it is possible that the avidity of TCR in vivo are not a major determinant of tumor rejection. It is likely that factors such as lymphocyte homing to normal versus tumor tissue, heterogeneity of antigen expression by tumor, T cell exhaustion, suppression in the tumor microenvironment or the need for polyvalent T
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cell populations may all need to be considered to improve tumor rejection in patients.
Murine tumor models predict that intensifying the lymphodepletion prior to cell transfer and administering a vaccine to stimulate the transferred cells in vivo can improve the anti-tumor efficacy of this approach 10, 23 and we are currently implementing a clinical trial combining the DMF5 and gp100(154) TCR, with increased patient immunodepletion, followed by administration of a peptide vaccine.
ACT therapy using gene-modified lymphocytes has also been shown to be effective in treating malignancies other than melanoma. In pre-clinical models, lymphocytes have been genetically modified to express costimulatory molecules designed to increase antitumor activity and T cell survival such as CD80 or 4-1BB ligand, or to abrogate the effects of inhibitory signals 24 . Genetically modified human lymphocytes expressing chimeric antigen receptors (CAR) 25 , combining the antigen-recognition of an antibody with T cell signaling motifs, were able to eradicate human B cell lymphoma by targeting CD19 26 , and human prostate tumors by targeting ErbB2/Her2 27 in xenogeneic SCID mouse models. Using Epstein-Barr virus (EBV)-specific human T cells transduced with CAR recognizing the Hodgkin lymphoma-specific CD30 antigen has also been shown to be effective in a xenogeneic mouse model 28 . Clinically, EBV-specific cells expressing CAR that recognize the neuroblastoma tumor-specific diasialoganglioside GD2 have also recently been used to successfully treat patients with neuroblastoma 29 .
In an attempt to expand this TCR therapy to treat cancers other than just melanoma, we have now cloned the genes encoding high avidity TCR that recognize a variety of analyzed the data, to which all authors have access.
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